ANI Pharmaceuticals Inc. has launched Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall U.S. market for Vancomycin HCl Capsules is approximately $113 million, according to IMS Health.

“We are pleased to announce the launch of our authorized generic to Vancocin, which replaces the authorized generic previously on the market,” said Arthur Przybyl, president and chief executive officer, ANI Pharmaceuticals. “This is the second of four generic products we plan to launch before the end of 2015, having previously announced the launch of Oxycodone Oral Solution in October. The launch of an authorized generic for one of our acquired branded products represents an important value driver for ANI and a key component of our mature brand strategy.”

Vancomycin Hydrochloride Capsules are indicated for the treatment of C. difficile-associated diarrhea. Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections.